Use of a novel transmembrane protein of Lrig-1 in a regulatory T cell
KR20210007916A
A composition for preventing, alleviating or treating immune checkpoint inhibitor resistant cancer
WO2021002735A1
Cell surface antigen of t cell and various uses thereof
WO2020190104A1
Composition for preventing or treating brain and nervous system disease
KR20200097654A
A Method for activating T cells to treat cancer
US2020239532A1
Recombinant fusion protein of baf57 and uses thereof
WO2020080853A1
Binding molecule specific to lrig-1 protein, and use thereof
KR20210017449A
A new fusion protein and use of tereof
CA3107159A1
Composition for preventing or treating immune-related diseases
BR112020022655A2
regulatory T cell surface antigen epitope and antibody that specifically binds to the same
WO2019209078A1
Novel fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same
WO2019132610A1
Recombinant baf57 fusion protein and use thereof
EP3719032A2
Composition for prevention or treatment of hair loss
CN110997903A
Method of activating T cells for cancer therapy
CN110799212A
DKK1 protein specifically present in regulatory T cells and uses thereof
CN110799534A
Specific binding molecules for LRIG-1 proteins and uses thereof
AU2016385177A1
Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof
EP3424946A2
A fusion protein having transcription modulating domain and a protein transduction domain, and an inhibitor for transcription factor function comprising the same
